Mirabegron may be an effective treatment for children with idiopathic overactive bladder (OAB), according to a new study.
The prospective off-label study, by Anne-Sophie Blais, MD, CHU de Québec-Université Laval, Québec, Québec, and colleagues, recruited 58 pediatric OAB patients who had no symptom improvement with behavioral or medical treatments and/or significant side effects with at least 2 different antimuscarinic agents. The patients had a median age of 10.1 years and were on mirabegron for a median of 11.5 months. Patients’ median bladder capacity improved from 150 to 200 mL and continence improved in 52 patients (89.6%), with 13 being completely dry, the researchers reported online ahead of print in European Urology.
“Mirabegron, a novel first-in-class therapy, appeared as a safe and effective alternative for children with idiopathic OAB refractory to antimuscarinics,” the authors concluded.
